APC

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Retrieved on: 
Thursday, March 28, 2024
Narcolepsy, Toxicity, Administration, Development, ASH, ABR, Haemophilia, Part, APC, Tumor microenvironment, Observation, Volunteering, Trial of the century, CD47, Investment, Society, Bleeding, CNTA, ATM, Safety, OX2R, Sleep, Person, Pharmaceutical industry

“This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

Key Points: 
  • “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
  • Cash, Cash Equivalents and Short-term Investments: $256.5 million as of December 31, 2023, which includes approximately $6.2 million in net proceeds through ATM sales in the fourth quarter ended December 31, 2023.
  • General & Administrative Expenses: $12.3 million for the fourth quarter ended December 31, 2023, compared to $13.8 million the fourth quarter ended December 31, 2022, and $53.7 million for the full-year 2023 compared to $55.2 million for the full-year 2022.
  • Net Loss Attributable to Ordinary Shareholders: $36.8 million for the fourth quarter ended December 31, 2023, compared to $43.2 million for the fourth quarter ended December 31, 2022, and $151.1 million for the full-year 2023 compared to $216.2 million for the full-year 2022.

Super Lawyers® 2024 Rising Stars Award Winner Joins Moore, Schulman & Moore, APC

Retrieved on: 
Friday, April 5, 2024
SAN, APC, Family law, University, Dean, Keen, Paternity, UCLA

SAN DIEGO, April 5, 2024 /PRNewswire/ -- Moore, Schulman & Moore, APC is excited to announce that Kimberly Keen is joining San Diego's Family Law experts. "Kimberly is a great addition to our team. Not only does her experience make her a great asset for our firm but the way she connects with clients and provides personalized service makes her a great asset for the people who trust us with their family law needs," says Moore, Schulman & Moore Founding Partner, David Schulman.

Key Points: 
  • SAN DIEGO, April 5, 2024 /PRNewswire/ -- Moore, Schulman & Moore, APC is excited to announce that Kimberly Keen is joining San Diego's Family Law experts.
  • Kimberly's legal prowess and professional achievement are recognized by Super Lawyers® 2024 with its Rising Stars award.
  • Kimberly employs a results-oriented and pragmatic approach to her cases, to limit the emotional and financial costs of protracted litigation.
  • She is committed to her community, her clients and her craft," says Moore, Schulman & Moore Founding Partner, Erik Moore.

Fujifilm Receives 510(k) Clearance for CAD EYE®, New AI-Powered Endoscopic Imaging Technology for Colonic Polyp Detection

Retrieved on: 
Wednesday, March 20, 2024
Colonoscopy, LCI, Documentation, Adenoma, EYE, Colorectal cancer, Conditional sentence, Risk, White Light, Polyp, APC, Assist, AI, Woman, Workflow, System, Safety, Swedish Health Services, Endoscopy, FDA, Health, CAD, Medical device

Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.

Key Points: 
  • Lexington, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation , a leading provider of endoscopic imaging and endosurgical solutions, received 510(k) clearance for CAD EYE, the company’s novel AI detection system for endoscopic imaging.
  • CAD EYE® enables real-time detection of colonic mucosal lesions such as polyps and adenomas during colonoscopy procedures, supporting endoscopists in their ability to detect and remove pre-cancerous lesions, regardless of size, shape and color.
  • Consisting of a compatible expansion unit (the Fujifilm EX-1) and endoscopy support software (EW10-EC02), CAD EYE is an evolution of Fujifilm’s ELUXEO® Endoscopic Imaging System, featuring AI image processing functionality customized for the integration with the system’s processor and the endoscope.
  • CAD EYE, ELUXEO and LCI are registered trademarks of FUJIFILM Corporation in various jurisdictions.

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Retrieved on: 
Wednesday, March 13, 2024
COL7, FAP, Cancer, Patient, APC, Mouse, ALM, Ribosome, BME, Gastrointestinal disease, OTC, Skin, Polyp (medicine), Therapy, Kidney, Pharmaceutical industry

BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.

Key Points: 
  • BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.
  • Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases.
  • ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
  • The drug candidate is expected to shortly enter into Phase I development in healthy volunteers.

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Surgery, Health Technology, Health Insurance, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Optical, Retina, IOP, HCPCS, Glaucoma, Ocular hypertension, OAG, OHT, Patient, Corporation, APC, Eye, Surgeon, CPT, Travoprost, GKOS, OPPS, Idose, Medicare, CMS, Government, Intraocular pressure

The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.

Key Points: 
  • The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
  • It is expected to increase patient access in the U.S. and has been published here on the CMS website.
  • “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCPCS, Interest, Second Half, Patient, APC, Sale, Society, University, Bank statement, Investment, Therapy, Marketing, DCR, Webcast, Hepatocellular carcinoma, CMS, Abdominal ultrasonography, Vein, Disease, Opinion, Immunotherapy, Safety, Manuscript, Cholangiocarcinoma, Pancreas, PFS, FDA, Liver disease, HCC, OS, Uveal melanoma, MDSC, Growth, TACE, Commander, U.S. Pacific Fleet, Drug, MD Anderson Cancer Center, Data, Medicare, Liver, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • This new code, HCPCS 9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 – Level 4 Endovascular Procedures.
  • The Company is working diligently to evaluate the materiality of the errors to determine whether any corrections for the third quarter financial results are required and to complete the Company’s year-end 2023 financial statements.
  • Operating losses were $14.1 million and $54.2 million, respectively, for the fourth quarter and full year ended December 31, 2023.

Global Armored Vehicles Market Top Player Analysis: Strong Global Demand for Armored Vehicles geared towards Fleet Recapitalization & Growth, Capabilities Advancement and Modernization - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Off-Road Trucks & SUVs, Defense, Other Defense, Automotive, Comparative, Infantry fighting vehicle, Leclerc, Oshkosh Corporation, Vehicle, Shock, M1 Abrams, Armoured personnel carrier, M113, AMPV, SWOT analysis, History, Acquisition, Food, K2 Black Panther, APC, Infantry, General Dynamics, Army, Houthi movement, Movement, Challenger, BAE Systems, Arms industry

The demand for armored vehicles has seen a major surge with their extensive utilization during the ongoing Russia-Ukraine war.

Key Points: 
  • The demand for armored vehicles has seen a major surge with their extensive utilization during the ongoing Russia-Ukraine war.
  • However, any further, major potential shock at this time could send the global economy spiraling down into a recessionary cycle.
  • The report provides a Comparative SWOT Analysis and Comprehensive Insights into the Global Top 5 Armored Vehicles Manufacturers with focus on a blend of quantitative & qualitative analysis.
  • The report provides detailed analysis on the Global Top 5 Armored Vehicle OEMs, including:

Global Armored Vehicles Market Outlook Report 2024: Emerging & Game Changer Technologies, Enhancements in Mobility, Firepower & Protection, Doctrinal Changes & Capabilities Advancement - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Other Transport, Automotive, Transport, Military, Automotive Manufacturing, Manufacturing, Other Automotive, Performance & Special Interest, Defense, Players, Houthi movement, Research, Challenge, Risk, T-90, Original equipment manufacturer, Shock, Firepower, Doctrine, Food, Forecast, APC, Strategic Insights, Movement, Value chain

The "Global Armored Vehicles Market - 2024 - Predictive Market Outlook for 2024 - Key Trends, Strategic Insights, Growth Opportunities & Market Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Armored Vehicles Market - 2024 - Predictive Market Outlook for 2024 - Key Trends, Strategic Insights, Growth Opportunities & Market Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Against this backdrop, the report provides comprehensive insights and analysis and a predictive market outlook on the Global Armored Vehicles Market.
  • Key Industry, Market & Technology Trends - Emerging & Game Changer Technologies, Enhacements in Mobility, Firepower & Protection, Doctrinal Changes & Capabilities Advancement.
  • The report would be indispensable for those having strategic interest & stakes in the Global Armored Vehicles Market.

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

Retrieved on: 
Wednesday, March 13, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, COL7, FAP, Cancer, Patient, APC, Mouse, ALM, Ribosome, BME, Gastrointestinal disease, OTC, Skin, Polyp (medicine), Therapy, Kidney, Pharmaceutical industry

Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.

Key Points: 
  • Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.
  • Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases.
  • ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
  • The drug candidate is expected to shortly enter into Phase I development in healthy volunteers.

Fuel Tech Awarded Air Pollution Control Orders Totaling $2.1 Million

Retrieved on: 
Monday, March 11, 2024
Technology, Manufacturing, Other Energy, Nuclear, Utilities, Other Technology, Other Manufacturing, Oil, Gas, Alternative Energy, Energy, Engineering, Municipal solid waste, SCR, Natural gas, Growth, APC, Metal, Selective non-catalytic reduction, Carbon, Corrosion, FUEL, NOx, SNCR, CHEM, Ammonia, Urea, Coal

Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering for the optimization of combustion systems, emissions control and water treatment in utility and industrial applications, today announced the receipt of air pollution control (APC) and Chemical Technologies orders from new and existing customers in Europe, the US and the Caribbean.

Key Points: 
  • Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering for the optimization of combustion systems, emissions control and water treatment in utility and industrial applications, today announced the receipt of air pollution control (APC) and Chemical Technologies orders from new and existing customers in Europe, the US and the Caribbean.
  • The first order is for a natural gas and process gas fired heater used at a chemical processing plant.
  • Fuel Tech’s SNCR technology is a proven solution for utility and industrial combustion unit owners looking to comply with more stringent NOx control requirements.
  • Fuel Tech’s range of technologies continues to provide value to support the needs of a wide range of industrial and utility operations.”